Preparation of Porphyra Extract-Containing Nanoemulsions and Evaluation of Their Effects on Ameliorating Candida Albicans Infection(1/3)

View Statistics Email Alert RSS Feed

Information

Details

Project title

Code/計畫編號

MOST109-2221-E019-032-MY3

Translated Name/計畫中文名

含紫菜萃取物奈米乳液之製備及其減緩白色念珠菌感染效用(1/3)

Project Coordinator/計畫主持人

Chung-Hsiung Huang

Funding Organization/主管機關

National Science and Technology Council

Co-Investigator(s)/共同執行人

黃明熙

Department/Unit

Department of Food Science

Website

https://www.grb.gov.tw/search/planDetail?id=13542588

Year

2020

Start date/計畫起

01-08-2020

Expected Completion/計畫迄

31-07-2021

Bugetid/研究經費

1256千元

ResearchField/研究領域

食品科技(工)

研究顯示紫菜內具有許多抗微生物及免疫調節活性成分。然而，這些活性成分經黏膜投予受限於消化酶、黏液、抗體、菌叢等因素造成其生體可用率下降。乳液已被發展為藥物遞送系統，可有效傳遞水溶性及脂溶性成分。過去研究報導奈米粒子作為黏膜型佐劑可有效增強疫苗效用，顯示奈米粒子對於黏膜通透性及免疫系統具調節活性。因此本計畫欲以紫菜萃取物作為活性成分，開發及製備其微米級及奈米級乳液。除了比較不同劑型之物化特性外，將以小鼠白色念珠菌感染模式評估經口及經陰道投予含紫菜萃取物(奈米)乳液減緩感染及抗發炎之功效。第一年的研究工作包括(1)萃取紫菜多醣、寡醣、藻紅蛋白及脂溶性成分；(2)以均質系統製備含紫菜萃取物乳液並分析其物化性質、穩定性及緩釋效用；(3)以擠壓系統及微流道高壓均質系統加工為奈米乳液並分析其物化性質、穩定性及緩釋效用。第二年研究工作包括：(1)離體測試含紫菜萃取物(奈米)乳液之抗白色念珠菌活性及其與fluconazole之協同效用；(2)離體測試含紫菜萃取物(奈米)乳液對於L929細胞存活率、脂多醣誘導巨噬細胞抗發炎作用及黏膜上皮細胞存活率及功能之影響。第三年的研究工作包括(1)經口投予含紫菜萃取物(奈米)乳液減緩小鼠白色念珠菌感染之效用；(2)經陰道投予含紫菜萃取物(奈米)乳液減緩小鼠白色念珠菌陰道感染之效用；(3)分析含紫菜萃取物(奈米)乳液投予後對於腸道及陰道菌叢及免疫之影響。基於上述實驗設計，預期可篩選出至少一種具減緩白色念珠菌感染之含紫菜萃取物(奈米)乳液配方。除了抗念珠菌活性，此計畫成果也可釐清這些乳液配方對於黏膜菌叢及免疫之影響。預期含紫菜萃取物(奈米)乳液配方可開發為改善消化道及女性生殖道黏膜菌叢失衡及抗發炎之天然保健產品。It has been reported the antimicrobial and immunomodulatory activities of Porphyra-derived ingredients. However, transmucosal administration of these ingredients results in poor bioavailability due to the interference of digestive enzymes, mucus, antibodies, microflora, etc. Emulsions have been developed as a drug delivery system that can effectively deliver hydrophilic and lipophilic ingredients. Previous studies have reported that nanoparticle as a mucosal adjuvant can effectively enhance the potency of vaccines, revealing that nanomaterials could regulate the mucosal permeability and immune responses. Therefore, this project aims to employ Porphyra extracts as active ingredients for the development and preparation of Porphyra extract-containing micron- and nano-scale emulsions. In addition to compare the physicochemical properties of different emulsion formulations, oral and intravaginal administration of Porphyra extract-containing (nano)emulsions will be employed to evaluate their effects on attenuating infection and inflammation in a murine model of Candida albicans infection. In the first year, planed works include: (1) extraction of polysaccharides, oligosaccharides, phycoerythrin and lipophilic components of Porphyra sp.; (2) preparation of Porphyra extract-containing emulsions with a homogeneous system and analysis of their physicochemical properties, stability and controlled-release efficiency; (3) processing emulsions into nano-scale via the extrusion system and microfluidics high pressure homogenizers and analyzing their physicochemical properties, stability, and controlled-release efficiency. In the second year, planed works include: (1) evaluation of in vitro anti-candida activity of Porphyra extract-containing (nano)emulsions and their synergistic effect with fluconazole; (2) investigation of the impact of Porphyra extract-containing (nano)emulsions on the survival rate of L929 cell, the activation and inflammation of lipopolysaccharide-induced macrophages, and the survival rate and functionality of Caco-2 mucosal epithelial cells. In the third year, the applicant will explore: (1) the effect of oral administration of Porphyra extract-containing (nano)emulsions on attenuating infection and inflammation in a murine model of C. albicans infection; (2) the effect of intravaginal administration of Porphyra extract-containing (nano)emulsions on attenuating infection and inflammation in a murine model of C. albicans infection; (3) the impact of Porphyra extract-containing (nano)emulsions on enteric and vaginal microbiota and immune responses.Based on the above experimental design, it is expected that at least one formulation of Porphyra extract-containing (nano)emulsion effectively against C. albicans infection will be developed. In addition to the anti-candida activity, the impact of Porphyra extract-containing (nano)emulsions on mucosal microbiota and immune responses will be clearly elucidated. The developed emulsion formulations are potential to be developed as natural health products for oral and/or intravaginal administration against mucosal dysbiosis and inflammation occurred in the digestive tract and female reproductive tract.

Keyword(s)

紫菜萃取物
奈米乳液
白色念珠菌
腸道菌叢
陰道菌叢
免疫反應
黏膜
Porphyra extract
nanoemulsions
Candida albicans
enteric microbiota
vaginal microbiota
immune responses
mucosa

DSpace CRIS

Preparation of Porphyra Extract-Containing Nanoemulsions and Evaluation of Their Effects on Ameliorating Candida Albicans Infection(1/3)

Details

Description